

Ríocht Aontaithe, an-Briostó: Pathology services

OJ S 21/2020 30/01/2020

Fógra trédhearcachta ex ante deonach

Seirbhísí

Bunús dlí:

Treoir 2014/24/AE

Alt I: Aonán/údarás conarthachta

I.1. Ainm agus seoltaí

Ainm oifigiúil: North Bristol NHS Trust

Seoladh poist: Southmead Road, Bristol

Baile: Bristol

Cód NUTS: UKK11 Bristol, City of

Cód poist: BS10 5NB

Tír: An Ríocht Aontaithe

Teagmhálaí: Martin Strawson

Ríomhphost: martin.strawson@UHBristol.nhs.uk

Guthán: +44 1173420815

Seoladh/seoltaí idirlín:

Príomhsheoladh: <https://www.nbt.nhs.uk/>

I.4. An cineál údaráis chonarthachta

Cineál eile: NHS trust

I.5. Príomhghníomhaíocht

Sláinte

Alt II: Cuspóir

II.1. Raon feidhme an tsoláthair

II.1.1. Teideal

Procurement of a Large Throughput DNA Sequencer

Uimhir thagartha: BWPCCL001501

II.1.2. Príomhchód CPV

85111800 Pathology services

II.1.3. An cineál conartha

Seirbhísí

II.1.4. Cur síos achomair

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Faisnéis faoi bhearta

Tá an conradh seo roinnte ina bhearta: níl

II.1.7. Luach iomlán an tsoláthair

Luach gan CBL san áireamh: 779 625,00 GBP

II.2. Cur síos

II.2.2. Cód(Cóid) CPV breise

85111000 Hospital services

II.2.3. Láthair feidhmíochta

Cód NUTS: UKK11 Bristol, City of

II.2.4. Cur síos ar an soláthar

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Critéir dámhachtana

Critéar cáilíochta - Ainm: Quality / Ualú: 90

Praghas - Ualú: 10

II.2.11.

Faisnéis faoi roghanna

Roghanna: níl

II.2.13. Faisnéis faoi Chistí an Aontais Eorpaigh

Baineann an soláthar le tionscadal agus/nó clár arna mhaoiniú ag cistí an Aontais Eorpaigh: níl

II.2.14. Faisnéis bhreise

Alt IV: Nós imeachta

IV.1. Cur síos

IV.1.1. An cineál nós imeachta

Conradh a dhámhachtain gan fógra conartha a fhoilsiú roimh ré in Iris Oifigiúil an Aontais Eorpaigh sna cásanna atá liostaithe thíos

- Tá an soláthar lasmuigh de raon feidhme na Treorach

Míniúchán:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Faisnéis faoin gcomhaontú creatlaí

IV.1.8. Faisnéis faoi Chomhaontú Soláthair Rialtais (GPA)

Tá an soláthar cumhdaithe ag an gComhaontas Soláthair Rialtais: níl

IV.2. Faisnéis riaracháin

Alt V: Dámhachtain an chonartha/lamháltais

Teideal:

Procurement of Large High Throughput DNA Sequencer

V.2. Dámhachtain an chonartha/lamháltais

V.2.1. Dáta an chinnidh faoi dhámhachtain an chonartha

28/01/2020

V.2.2. Faisnéis faoi thairiscintí

Dámhadh an conradh do ghrúpa oibreoirí eacnamaíocha: níl

V.2.3. Ainm agus seoladh an chonraitheora/an lamháltóra

Ainm oifigiúil: Illumina Cambridge Ltd

Seoladh poist: Chesterford Research Park, Little Chesterford

Baile: Saffron Walden

Cód NUTS: UKI London

Cód poist: CB10 1XL

Tír: An Ríocht Aontaithe

Beidh an conraitheoir/lamháltóir ina FBM: tá

V.2.4. Faisnéis faoi luach an chonartha/an bhirt/an lamháltais

Luach iomlán an chonartha/an bhirt/an lamháltais: 779 625,00 GBP

V.2.5. Faisnéis faoi fhoichonraitheoireacht

Alt VI: Faisnéis chomhlántach

VI.3. Faisnéis bhreise

VI.4. Nósanna imeachta athbhreithniúcháin

VI.4.1. Comhlacht athbhreithniúcháin

Ainm oifigiúil: Bristol and Weston Purchasing Consortium

Seoladh poist: Level 3, Whitefriars, Lewins Mead

Baile: Bristol

Cód poist: BS1 2NT

Tír: An Ríocht Aontaithe

Ríomhphost: martin.strawson@UHBristol.nhs.uk

VI.4.2. Comhlacht atá freagrach as nósanna imeachta idirghabhála

Ainm oifigiúil: Bristol and Weston Purchasing Consortium

Seoladh poist: Level 3, Whitefriars, Lewins Mead

Baile: Bristol

Cód poist: BS1 2NT

Tír: An Ríocht Aontaithe

VI.4.4. Seirbhís ónar féidir faisnéis a fháil faoin nós imeachta athbhreithniúcháin

Ainm oifigiúil: Bristol and Weston Purchasing Consortium

Seoladh poist: Level 3, Whitefriars, Lewins Mead

Baile: Bristol

Cód poist: BS1 2NT

Tír: An Ríocht Aontaithe

VI.5. Dáta seolta an fhógra seo

28/01/2020